|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||4,951.05 - 5,497.00|
|52 Week Range||2,497.60 - 5,497.00|
|Beta (5Y Monthly)||0.13|
|PE Ratio (TTM)||47.41|
|Earnings Date||Oct 30, 2020 - Nov 03, 2020|
|Forward Dividend & Yield||25.00 (0.52%)|
|Ex-Dividend Date||Jul 13, 2020|
|1y Target Est||2,581.68|
Bristol-Myers Squibb has come to terms on an agreement to delay entry of a generic version of its multiple myeloma drug, Revlimid.
India's Dr. Reddy's Labs announced a pact to assist with clinical trials for Russia's Sputnik V coronavirus vaccine and to get 100 million doses of the vaccine; RDY stock rose to a buy zone.
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy’s"), today announced the settlement of their litigation with Celgene, a wholly owned subsidiary of Bristol Myers Squibb (NYSE: BMY), relating to patents for REVLIMID® (lenalidomide) Capsules.